Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

582
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
582
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

821
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
821
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

240
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
240
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

219
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
219
Phosphoinositides and PIPs01:42

Phosphoinositides and PIPs

8.6K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
8.6K

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Unveiling the Role of Hydroxyls on Catalyst Surface in CO<sub>2</sub> Hydrogenation Reaction.

Angewandte Chemie (International ed. in English)·2026
Same author

Balancing metabolic optimization and reproductive safety in Polycystic Ovary Syndrome: a Bayesian-informed framework for GLP-1 receptor agonists.

Frontiers in nutrition·2026
Same author

Vitamin D as a cellular endocrine system: Tissue-specific microcircuits, immune reprogramming, and metabolic resistance.

iScience·2026
Same author

Dietary fiber and total fat intake density and self-reported cancer history in U.S. adults: NHANES 2021-2022.

Cancer treatment and research communications·2026
Same author

Pharmacophore Directed Retrosynthesis Applied to Waixenicin A: Synthesis and Bioactivity of Derivatives Bearing a Minimal Proposed Pharmacophore.

Organic letters·2026
Same author

Tectono-paleogeographic evolution of the Northern Margin of the North China Block based on provenance analysis of Jurassic strata in Liaodong Peninsula.

Scientific reports·2026

関連する実験動画

Updated: Aug 12, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

強力な抗血栓剤としてのピエリコーンAとB:予期せぬ化学構造を持つナノモラー非競争性タンパク質ジスルファイドイソメラーゼ阻害剤

Guijuan Zheng1, Keyu Lv2, Hao Wang2

  • 1Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation, School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, People's Republic of China.

Journal of the American Chemical Society
|January 25, 2023
PubMed
まとめ

ピアリス・ジャポニカから4つの新しい化合物であるピエリコーンA-Dが発見され,細胞外タンパク質二硫化同化酵素 (PDI) の強力な阻害剤として特定されました. 血栓形成を抑制し,出血リスクを増加させない.

さらに関連する動画

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
Synthesis and Structure Determination of &#181;-Conotoxin PIIIA Isomers with Different Disulfide Connectivities
11:44

Synthesis and Structure Determination of µ-Conotoxin PIIIA Isomers with Different Disulfide Connectivities

Published on: October 2, 2018

12.7K

関連する実験動画

Last Updated: Aug 12, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

21.9K
Synthesis and Structure Determination of &#181;-Conotoxin PIIIA Isomers with Different Disulfide Connectivities
11:44

Synthesis and Structure Determination of µ-Conotoxin PIIIA Isomers with Different Disulfide Connectivities

Published on: October 2, 2018

12.7K

科学分野:

  • 自然製品 化学
  • 薬剤化学
  • 生物化学

背景:

  • 細胞外タンパク質二酸化イソメラーゼ (PDI) は,血栓性疾患の重要な要因である.
  • PDIの標的化阻害剤の開発は,これらの状態のための治療戦略を提供します.

研究 の 目的:

  • 新しい PDI 阻害剤を天然源から分離し,特徴づけること.
  • これらの阻害剤の抗血栓的可能性を評価する.

主な方法:

  • A-Dピエリコンの分離と構造の解明は,光譜データ,化学方法,量子NMR,ECD計算,X線結晶学を用いて行われます.
  • PDI阻害運動を決定する生化学的測定
  • インビトロとインビボの抗血栓活性評価
  • 分子ドッキングとダイナミクスシミュレーション

主要な成果:

  • ピエリス・ジャポニカから4つの新しい化合物,ピエリコーンA-Dが分離されました.
  • ピエリコーンAとBは,独特の化学構造と9つのステレオジェニックセンターを持つ強力な非競争性PDI阻害剤です.
  • Piericone Aは,細胞外PDIを標的として,血小板の集積,フィブリン形成,および体内の血栓形成を有意に抑制することが示された.
  • Piericone Aの治療では出血のリスクは増加しなかった.
  • 分子シミュレーションにより,ピエリコーンAとピエリコーンBの結合メカニズムに関する洞察が得られた.

結論:

  • Piericones A-Dは,前例のない構造を持つ新しいPDI阻害剤のクラスを表しています.
  • Piericone Aは強力な抗血栓活性と良好な安全性プロファイルを示し,さらなる薬の開発に有望な候補となる.
  • この研究は,新しいPDI阻害剤を抗血栓剤として設計するための構造的基礎を提供します.